Bristol-Myers Squibb's taxol NDA
Executive Summary
Filed in the U.S. on July 22 for an undisclosed indication. Based on early clinical trial results reported by the National Cancer Institute, the company probably is seeking approval of the drug for use in refractory ovarian cancer. Bristol-Myers Squibb also announces that it "is voluntarily relinquishing 'orphan drug' status previously granted to taxol." Advanced metastatic ovarian cancer patients have expanded access to taxol under a Treatment IND ("The Pink Sheet" July 20, In Brief).